Chemo, immunotherapy, and targeted radiation join forces against bile duct cancer
NCT ID NCT05422690
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study tests whether combining chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab) and a targeted radiation treatment (Yttrium-90 microspheres) can shrink tumors in people with locally advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination works better than standard treatments at controlling the disease. Participants receive the drugs first, followed by the radiation therapy directly into the liver tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine, cisplatin, durvalumab, and Yttrium-90 microspheres
- What this could lead to
- If successful, this combination could offer a new treatment option for people with inoperable bile duct cancer, potentially shrinking tumors and extending life.
- What could go wrong
- This is a small, early-phase trial with only 16 participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from chemotherapy, immunotherapy, and radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Keary Janet
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Liver tumors targeted directly: old pump, new drug
- New combo attack on untreatable liver cancer shows promise in early trial
- Zapping spreading tumors could extend life on current cancer drugs